- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.11. | BRAIN A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant | 1 | Cision News | ||
| 21.10. | BRAIN A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy | 1 | Cision News | ||
| BRAIN+ A/S Aktie jetzt für 0€ handeln | |||||
| 11.10. | BRAIN A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions | 1 | Cision News | ||
| 07.10. | BRAIN A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue | 1 | Cision News | ||
| 02.10. | BRAIN A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market | 1 | Cision News | ||
| 01.10. | BRAIN A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions | 2 | Cision News | ||
| 25.09. | BRAIN A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK | 3 | Cision News | ||
| 23.09. | BRAIN A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization | 2 | Cision News | ||
| 20.09. | BRAIN A/S: Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4% | 2 | Cision News | ||
| 17.09. | BRAIN A/S: Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4 | 1 | Cision News | ||
| 13.09. | BRAIN A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027 | 1 | Cision News | ||
| 13.09. | BRAIN A/S: Brain+ A/S announces the exercise price for its warrants of series TO 4 | 1 | Cision News | ||
| 05.09. | BRAIN A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment | 1 | Cision News | ||
| 29.08. | BRAIN A/S: H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected | 2 | Cision News | ||
| 23.08. | BRAIN A/S: Brain+ fully on track towards market entry and first sales in the United Kingdom in H2 2024 | 1 | Cision News | ||
| 09.07. | First North Denmark: Brain+ A/S - increase and admittance to trading of TO 4 (warrants) | 239 | GlobeNewswire | New shares in Brain+ A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 11 July 2024. New shares are issued due to
completion of a rights issue of units consisting of... ► Artikel lesen | |
| 28.06. | BRAIN A/S: Brain+ hires UK health tech rising star as Chief Commercial Officer | 1 | Cision News | ||
| 27.06. | BRAIN A/S: Brain+ A/S publishes the outcome of its rights issue of units | 1 | Cision News | ||
| 24.06. | BRAIN A/S: Brain+ obtains additional guarantee commitment in its ongoing rights issue | 1 | Cision News | ||
| 20.06. | BRAIN A/S: Correction - Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue | 1 | Cision News |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 32,860 | +2,02 % | WARBURG RESEARCH stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Das Analysehaus Warburg Research hat das Kursziel für Fresenius von 44 auf 42 Euro gesenkt, aber die Einstufung auf "Buy" belassen. "Nächster Schritt: Revitalisierung",... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 92,70 | 0,00 % | Looking Into PROCEPT BioRobotics' Recent Short Interest | ||
| GERRESHEIMER | 69,10 | -1,50 % | Aixtron, Gerresheimer, Hugo Boss, K+S, Lufthansa, Rheinmetall u.a. - Aktien-Positionen der Shortseller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| ATRICURE | 36,030 | 0,00 % | Pre-market Movers: ASP Isotopes, NerdWallet, Reddit, AtriCure, Qorvo | OLATHE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green ASP Isotopes Inc. (ASPI) is up over 44% at $8.33.
NerdWallet... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 49,040 | -1,33 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Siemens Healthineers nach einer Investorenveranstaltung mit einem Kursziel von 65,90 Euro auf "Overweight" belassen. Die Themen... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 54,65 | -3,95 % | Carl Zeiss Meditec Aktie: Planänderungen erforderlich | Die Carl Zeiss Meditec-Aktie verzeichnete am Handelstag einen deutlichen Kursrückgang. Im XETRA-Handel fiel der Aktienkurs um 2,3 Prozent auf 56,65 Euro, nachdem er bei Börseneröffnung noch bei 58,65... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,620 | +2,01 % | DZ BANK stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Halten' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für FMC von 37 auf 41 Euro angehoben und die Einstufung auf "Halten" belassen. Der Dialyseanbieter habe ein gelungenes Quartal hinter sich... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 20,790 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2024 Financial Results | Strong Execution Across All Business and Financial MetricsRaised Full-Year 2024 Guidance to At or Above the High End for All MetricsAnnounced New Market Entry in Indiana Achieved MSSP 2023 Shared... ► Artikel lesen | |
| GENEDX | 69,40 | 0,00 % | GeneDx Holdings Corp. (NASDAQ:WGS) Major Shareholder Sells $8,973,629.96 in Stock | ||
| TEMPUS AI | 58,12 | 0,00 % | Cathie Wood's ARK ETFs Adjust Portfolio with Notable Tesla and Tempus AI Stock Trades | ||
| NANO-X IMAGING | 5,890 | 0,00 % | Nano-X Imaging LTD.: Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium | HealthCCSng V2.0 introduces additional 'zero calcium' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 11,980 | 0,00 % | Alignment Healthcare announces offering of $330M convertible debt | ||
| PROGYNY | 13,980 | 0,00 % | Barclays Lowers Progyny (NASDAQ:PGNY) Price Target to $17.00 | ||
| INTUITIVE SURGICAL | 518,60 | +0,88 % | Unglaubliche Prognose für Montag setzt Intuitive Surgical Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ENDRA LIFE SCIENCES | 5,070 | 0,00 % | ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update | ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months... ► Artikel lesen |
Das Unternehmen BRAIN+ A/S kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAIN+ A/S finden Sie auf Wallstreet Online.
